Krystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024. In the quarter to June 2026, revenue grew 24.1%, EPS grew 39.1% and free cash flow grew 40.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow KRYS
Krystal Biotech, Inc. (KRYS) EV/Sales
As of 16 October 2026, Krystal Biotech, Inc. (KRYS) trades at a EV/Sales of 19.3×. Over the past ten years it has ranged from 0.0× (June 2024) to 33.4× (July 2024); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 16.2× | 21.32% |
| FY2024 | 13.4× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 23.0× | 42.33% |
| Mar 2026 | 16.2× | (0.33%) |
| Dec 2025 | 16.2× | 38.11% |
| Sep 2025 | 11.7× | 28.07% |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| CAI Caris Life Sciences,�Inc. compare | 8.3× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 9.8× |
| KRYS Krystal Biotech, Inc. | 19.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 27.4× |
| IBRX ImmunityBio, Inc. compare | 63.6× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| CYTK Cytokinetics, Incorporated compare | 121× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)